Supplementary files: Long term safety of nine systemic medications for psoriasis: a cohort study using the Biobadaderm Registry
Published: 11 March 2020| Version 2 | DOI: 10.17632/w33yb7gsy4.2
Esteban Dauden Tello ,
Miguel Angel Descalzo
Supplementary Table 1S. Crude incidence rate ratios and adjusted incidence rate ratios of the adverse effects for each drug. Supplementary Table 2S. Detailed adverse events for each drug compared to MTX. Only those AE included in groups with a decreased rate ratio (IRR < 1, green in Table 3) and highly increased rate ratio (IRR > 5, red in Table 3) are shown.
Dermatology, Systemic Treatment, Psoriasis, Drug Safety